Merck Reports Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-091) Trial as Adjuvant Treatment for Stage IB-IIIA NSCLC
Shots:
- The P-III (KEYNOTE-091) trial evaluates Keytruda (200mg, IV, q3w) vs PBO in a ratio (1:1) in 1,177 patients with stage IB-IIIA NSCLC following surgical resection with/out adjuvant CT
- The trial met its 1EPs of DFS for patients with stage IB-IIIA NSCLC regardless of PD-L1 expression. In an interim analysis, the therapy showed an improvement in DFS in the all-comer population & whose tumors express PD-L1. The safety profile was consistent with previously reported studies
- The company has an extensive clinical development program in lung cancer. Keytruda is being evaluated in multiple registration-enabling studies in combination with other treatments & as monothx. for lung cancer
Ref: Businesswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com